High-flow nasal oxygen as first-line therapy for COVID-19-associated hypoxemic respiratory failure: a single-centre historical cohort study.

MLA

Schwartz, Blair Carl, et al. “High-Flow Nasal Oxygen as First-Line Therapy for COVID-19-Associated Hypoxemic Respiratory Failure: A Single-Centre Historical Cohort Study.” Canadian Journal of Anaesthesia = Journal Canadien d’anesthesie, vol. 69, no. 5, May 2022, pp. 582–90. EBSCOhost, https://doi.org/10.1007/s12630-022-02218-z.

APA

Schwartz, B. C., Jayaraman, D., Yang, S. S., Wong, E. G., Lipes, J., & Dial, S. (2022). High-flow nasal oxygen as first-line therapy for COVID-19-associated hypoxemic respiratory failure: a single-centre historical cohort study. Canadian Journal of Anaesthesia = Journal Canadien d’anesthesie, 69(5), 582–590. https://doi.org/10.1007/s12630-022-02218-z

Chicago

Schwartz, Blair Carl, Dev Jayaraman, Stephen Su Yang, Evan G Wong, Jed Lipes, and Sandra Dial. 2022. “High-Flow Nasal Oxygen as First-Line Therapy for COVID-19-Associated Hypoxemic Respiratory Failure: A Single-Centre Historical Cohort Study.” Canadian Journal of Anaesthesia = Journal Canadien d’anesthesie 69 (5): 582–90. doi:10.1007/s12630-022-02218-z.